Gotowe bibliografie tematyczne / Pneumococcal vaccine

Spis treści

  1. Artykuły w czasopismach
  2. Rozprawy doktorskie
  3. Książki
  4. Części książek
  5. Streszczenia konferencji
  6. Raporty organizacyjne

Gotowa bibliografia na temat „Pneumococcal vaccine”

Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 25 lipca 2025

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Pneumococcal vaccine”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Pneumococcal vaccine"

1

Gladstone, R. A., J. M. Jefferies, S. N. Faust, and S. C. Clarke. "Continued control of pneumococcal disease in the UK – the impact of vaccination." Journal of Medical Microbiology 60, no. 1 (2011): 1–8. http://dx.doi.org/10.1099/jmm.0.020016-0.

Pełny tekst źródła
Streszczenie:
Streptococcus pneumoniae, also known as the pneumococcus, is an important cause of morbidity and mortality in the developed and developing world. Pneumococcal conjugate vaccines were first introduced for routine use in the USA in 2000, although the seven-valent pneumococcal conjugate vaccine (PCV7) was not introduced into the UK's routine childhood immunization programme until September 2006. After its introduction, a marked decrease in the incidence of pneumococcal disease was observed, both in the vaccinated and unvaccinated UK populations. However, pneumococci are highly diverse and serotyp
Style APA, Harvard, Vancouver, ISO itp.
2

van Tonder, Andries J., James E. Bray, Lucy Roalfe, et al. "Genomics Reveals the Worldwide Distribution of Multidrug-Resistant Serotype 6E Pneumococci." Journal of Clinical Microbiology 53, no. 7 (2015): 2271–85. http://dx.doi.org/10.1128/jcm.00744-15.

Pełny tekst źródła
Streszczenie:
The pneumococcus is a leading pathogen infecting children and adults. Safe, effective vaccines exist, and they work by inducing antibodies to the polysaccharide capsule (unique for each serotype) that surrounds the cell; however, current vaccines are limited by the fact that only a few of the nearly 100 antigenically distinct serotypes are included in the formulations. Within the serotypes, serogroup 6 pneumococci are a frequent cause of serious disease and common colonizers of the nasopharynx in children. Serotype 6E was first reported in 2004 but was thought to be rare; however, we and other
Style APA, Harvard, Vancouver, ISO itp.
3

Peter, Georges, and Jerome O. Klein. "Pneumococcal Vaccine." Pediatrics In Review 17, no. 10 (1996): 335–41. http://dx.doi.org/10.1542/pir.17.10.335.

Pełny tekst źródła
Streszczenie:
Streptococcus pneumoniae, commonly termed the pneumococcus, is a major pediatric pathogen both in developed and developing countries. Despite the availability of multiple antimicrobials to which this organism is susceptible, it continues to cause significant morbidity and mortality. Recognition of the limitations of antimicrobial therapy in controlling the consequences of infection, particularly among high-risk persons such as those who have underlying pulmonary or cardiovascular disease and the elderly, led to the introduction in the 1970s of a polyvalent, polysaccharide pneumococcal vaccine.
Style APA, Harvard, Vancouver, ISO itp.
4

Sempere, Julio, Mirella Llamosí, Idoia del Río Menéndez, Beatriz López Ruiz, Mirian Domenech, and Fernando González-Camacho. "Pneumococcal Choline-Binding Proteins Involved in Virulence as Vaccine Candidates." Vaccines 9, no. 2 (2021): 181. http://dx.doi.org/10.3390/vaccines9020181.

Pełny tekst źródła
Streszczenie:
Streptococcus pneumoniae is a pathogen responsible for millions of deaths worldwide. Currently, the available vaccines for the prevention of S. pneumoniae infections are the 23-valent pneumococcal polysaccharide-based vaccine (PPV-23) and the pneumococcal conjugate vaccines (PCV10 and PCV13). These vaccines only cover some pneumococcal serotypes (up to 100 different serotypes have been identified) and are unable to protect against non-vaccine serotypes and non-encapsulated pneumococci. The emergence of antibiotic-resistant non-vaccine serotypes after these vaccines is an increasing threat. The
Style APA, Harvard, Vancouver, ISO itp.
5

Francois Watkins, Louise K., Jennifer L. Milucky, Lesley McGee,, et al. "Nasopharyngeal Carriage of Streptococcus pneumoniae Among Young Children in Haiti Before Pneumococcal Conjugate Vaccine Introduction." Journal of Infectious Diseases 224, Supplement_3 (2021): S248—S257. http://dx.doi.org/10.1093/infdis/jiab119.

Pełny tekst źródła
Streszczenie:
Abstract Background Streptococcus pneumoniae, or pneumococcus, is a leading cause of morbidity and mortality in children worldwide. Pneumococcal conjugate vaccines (PCV) reduce carriage in the nasopharynx, preventing disease. We conducted a pneumococcal carriage study to estimate the prevalence of pneumococcal colonization, identify risk factors for colonization, and describe antimicrobial susceptibility patterns among pneumococci colonizing young children in Port-au-Prince, Haiti, before introduction of 13-valent PCV (PCV13). Methods We conducted a cross-sectional study of children aged 6–24
Style APA, Harvard, Vancouver, ISO itp.
6

Browall, Sarah, Erik Backhaus, Pontus Naucler, et al. "Clinical manifestations of invasive pneumococcal disease by vaccine and non-vaccine types." European Respiratory Journal 44, no. 6 (2014): 1646–57. http://dx.doi.org/10.1183/09031936.00080814.

Pełny tekst źródła
Streszczenie:
Pneumococcal conjugated vaccines (PCVs) have shown protection against invasive pneumococcal disease by vaccine serotypes, but an increase in non-vaccine serotype disease has been observed. Type-specific effects on clinical manifestation need to be explored.Clinical data from 2096 adults and 192 children with invasive pneumococcal disease were correlated to pneumococcal molecular serotypes. Invasive disease potential for pneumococcal serotypes were calculated using 165 invasive and 550 carriage isolates from children.The invasive disease potential was lower for non-PCV13 compared to vaccine-typ
Style APA, Harvard, Vancouver, ISO itp.
7

A., Lagousi Theano, John Routsias, Athanasios Tsakris, Maria Papagrigoriou-Theodoridou, and Vana Spoulou. "Pneumococcus and new approaches for pneumococcal disease prevention." ACTA MICROBIOLOGICA HELLENICA 59, no. 2 (2014): 17–26. https://doi.org/10.5281/zenodo.10016399.

Pełny tekst źródła
Streszczenie:
Streptococcus pneumoniae (pneumococcus) is responsible for considerable morbidity and mortality worldwide predominantly in children younger than 2 years, the elderly over 65 years and immunocompromised individuals. Currently available pneumococcal vaccines are based on the generation of antibodies against polysaccharide capsule. Although these vaccines are effective against pneumococcal disease, their clinical effectiveness is limited due to several drawbacks. In particular, their high cost makes their widespread use difficult predominantly in developing countries. Αdditionally, the widespread
Style APA, Harvard, Vancouver, ISO itp.
8

PICHON, B., H. V. BENNETT, A. EFSTRATIOU, M. P. E. SLACK, and R. C. GEORGE. "Genetic characteristics of pneumococcal disease in elderly patients before introducing the pneumococcal conjugate vaccine." Epidemiology and Infection 137, no. 7 (2009): 1049–56. http://dx.doi.org/10.1017/s0950268808001787.

Pełny tekst źródła
Streszczenie:
SUMMARYStreptococcus pneumoniaestrains causing invasive pneumococcal disease (IPD) in the elderly population of England and Wales during the winter of 2003/2004 (1 November 2003 to 30 April 2004) were characterized by serotyping and genotyping in order to determine their population structure in the elderly. Serotyping and multilocus sequence typing (MLST) were carried out on 542 invasive isolates referred to the Respiratory and Systemic Infection Laboratory. Pneumococci were distributed among 32 serotypes and 144 MLST sequence types. A high genetic diversity was observed within the major serot
Style APA, Harvard, Vancouver, ISO itp.
9

Walekhwa, Michael, Fiona Maiyo, Teresa Kerubo, and Fred Kipsang. "In Vitro Evaluation of Effect of Storage Time on Immunogenicity of the 10-Valent Pneumococcal Conjugate Vaccine Using Baby Rabbit Complement & HL-60 Cells." Kabarak Journal of Research & Innovation 14, no. 01 (2024): 16–25. http://dx.doi.org/10.58216/kjri.v14i01.280.

Pełny tekst źródła
Streszczenie:
Background: The efficacy and effectiveness of a vaccine is influenced by several factors including storage duration. Additionally, vaccines may be sufficiently administered but functionality of antibody generated may be hampered with by other factors such as nutritional status of the patient. As such, one of the ways of assessing vaccine efficacy is assessing the functionality of the antibodies generated. The 10v-PCV is a highly effective vaccine used to prevent invasive pneumococcal diseases in children. However, here in Kenya, cases of pneumococcal diseases are high and challenging to treat.
Style APA, Harvard, Vancouver, ISO itp.
10

Ludwig, Endre, and Zsófia Mészner. "Prevention ofStreptococcus pneumoniae(pneumococcal) infections in adults." Orvosi Hetilap 155, no. 50 (2014): 1996–2004. http://dx.doi.org/10.1556/oh.2014.30070.

Pełny tekst źródła
Streszczenie:
Infections caused by Streptococcus pneumoniae (pneumococcus) are still meaning a serious health problem, about 40% of community acquired pneumonia (CAP) is due to pneumococcal bacteria in adults requiring hospitalization. The incidence and mortality rate of pneumococcal infections is increasing in the population above 50 years of age. Certain congenital and acquired immunocompromised conditions make the individual susceptible for pneumococcal infection and other chronic comorbidities should be considered as a risk factor as well, such as liver and renal diseases, COPD, diabetes mellitus. Letha
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Pneumococcal vaccine"

1

Lee, Lai-ka, and 李勵嘉. "The pattern of invasive pneumococcal disease in Hong Kong, other parts of China, United States and Thailand : a focus on impact of pneumococcal vaccination : a systematic review." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/206944.

Pełny tekst źródła
Streszczenie:
Objectives: By summarizing and comparing the pattern of invasive pneumococcal disease (IPD) in the 4 areas (namely Hong Kong, other parts of China, United States and Thailand) at different stages of implementation of universal pneumococcal vaccination, a snapshot picture could be obtained to visualize how pneumococcal vaccination has impacted upon various important measures, including the burden of IPD, prevalent serotypes, antimicrobial resistance, risk factors of IPD, to guide us on the next step to optimize our ability to combat against IPD. Methods: To achieve the objective, a systemati
Style APA, Harvard, Vancouver, ISO itp.
2

Wu, Yunyan, and 吴云燕. "The immunogenicity and safety of 13-valent pneumococcal conjugate vaccine: a systematic review." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B46943493.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Fan, Hiu-yan, and 樊曉欣. "Economic evaluation of the second generation pneumococcal conjugate vaccine in children : a systematic review." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/206903.

Pełny tekst źródła
Streszczenie:
Background Pneumococcal disease, caused by Streptococcus pneumoniae (S. pneumoniae), leads to a great burden of morbidity and mortality globally, especially in developing countries. World Health Organization (WHO) estimated that 476,000 out of 8.8 million global annual deaths in children under 5 years old in 2008 were due to pneumococcal infection. Currently there are 2 second generation pneumococcal conjugate vaccines (PCVs) targeted at children, the 10-valent pneumococcal conjugate vaccine (PCV-10) and 13-valent pneumococcal conjugate vaccine (PCV-13) available in the market for the preven
Style APA, Harvard, Vancouver, ISO itp.
4

Wong, Kwan-ting, and 王筠婷. "The cost-effectiveness of 13-valent pneumococcal conjugate vaccine for older adults : a systematic review." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/206978.

Pełny tekst źródła
Streszczenie:
BACKGROUND: Despite the current recommendation by the Centre for Health Protection (CHP)of Hong Kong for adults aged 65 years or above to receive 23-valent pneumococcal polysaccharide vaccine (PPV23), pneumococcal disease(PD) has become the second leading causes of death in Hong Kong. A relatively new pneumococcal vaccine –13-valent pneumococcal conjugate vaccine (PCV13) was approved by the US Food and Drug Administration (FDA) in December 2011 and the European Medicines Agency (EMA) in July 2013 for the prevention of invasive disease caused by S. pneumoniae for older adults aged 50 years or a
Style APA, Harvard, Vancouver, ISO itp.
5

Mitchell, Patrick Kevin. "Pneumococcal Population Dynamics in the Conjugate Vaccine Era." Thesis, Harvard University, 2016. http://nrs.harvard.edu/urn-3:HUL.InstRepos:27201746.

Pełny tekst źródła
Streszczenie:
The introduction of pneumococcal conjugate vaccines (PCVs) in the early years of the 21st century have led to significant changes in pneumococcal epidemiology. Using transmission modeling and genomics based approaches, this dissertation evaluates alterations to the pneumococcal population through the PCV era. Chapter 1 presents a transmission model designed to examine factors that may influence the potential of a previously rare antibiotic resistant lineages to emerge following the introduction of a vaccine targeting more common resistant types, finding that such emergence is more likely in se
Style APA, Harvard, Vancouver, ISO itp.
6

Coulibaly, Aissata. "Impact of Pneumococcal Conjugate Vaccine Thirteen Valent on the Reduction of Invasive Pneumococcal Disease." ScholarWorks, 2016. https://scholarworks.waldenu.edu/dissertations/2116.

Pełny tekst źródła
Streszczenie:
Many children under the age of 5 die each year of invasive pneumococcal disease. Childhood vaccination against this disease reduces morbidity and mortality. Despite the introduction of a pneumococcal conjugate vaccine (PCV13) in a central African country in 2011, all provinces have not yet been vaccinated. The purpose of this quantitative quasi-experimental study was to determine whether there was an association between the introduction of PCV13 and new cases of pneumococcal disease in 2 provinces in central Africa. The sample size for the study was 380. The theoretical framework for this stud
Style APA, Harvard, Vancouver, ISO itp.
7

Perez, Federico. "Challenges And Opportunities To Protect Veterans From Pneumococcal Disease: A “Virtual Clinic” Improves Vaccination." Case Western Reserve University School of Graduate Studies / OhioLINK, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=case1512685624555677.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Wadanambi, Arachchige Sanjay Harsha Jayasinghe. "Long-term impact and effectiveness of vaccines on invasive pneumococcal disease in Australian children." Thesis, The University of Sydney, 2019. http://hdl.handle.net/2123/20156.

Pełny tekst źródła
Streszczenie:
Pneumococcal disease is a leading cause of morbidity and mortality in children globally. Pneumococcal conjugate vaccines (PCVs), available since early 2000, had proven efficacy to prevent invasive pneumococcal disease (IPD)-the sever form of pneumococcal infections. For Australian children PCV had been publicly funded through the national immunisation program, initially in 2001 for those with increased disease risk which included Aboriginal and Torres Strait Islander children and from 2005 for all children. The schedule of PCV used in Australia comprising three doses at age 2, 4 and 6 months (
Style APA, Harvard, Vancouver, ISO itp.
9

Arana, Jorge E. "Comparison of Post-Licensure Safety Surveillance of 13-Valent Pneumococcal Conjugate Vaccine and 7-Valent Pneumococcal Conjugate Vaccine: Data from the Vaccine Advere Event Reporting System (Vaers)." Digital Archive @ GSU, 2011. http://digitalarchive.gsu.edu/iph_theses/159.

Pełny tekst źródła
Streszczenie:
Comparison of Post-licensure safety surveillance of 13-Valent Pneumococcal Conjugate vaccine and 7-Valent Pneumococcal Conjugate vaccine: Data from the Vaccine Adverse Event Reporting System (VAERS). Background: On February 24, 2010, Food and Drug Administration (FDA) licensed a 13-valent pneumococcal conjugate vaccine (Prevnar 13®, [PCV13]) for use among children aged 6 weeks--71 months. The Advisory Committee on Immunization Practices (ACIP) recommended PCV13 routine vaccination of all children aged 2--59 months, children aged 60--71 months with underlying medical conditions, with PCV13
Style APA, Harvard, Vancouver, ISO itp.
10

Kwambana, Brenda Anna. "Infant nasopharyngeal microbial ecology and the pneumococcal conjugate vaccine." Thesis, University of Leicester, 2011. http://hdl.handle.net/2381/10049.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Książki na temat "Pneumococcal vaccine"

1

R, Siber George, Klugman Keith P, and Mäkelä P. Helena, eds. Pneumococcal vaccines: The impact of conjugate vaccine. ASM Press, 2008.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

T, Mayon-White Richard, and Royal Society of Medicine (Great Britain), eds. The clinical impact of pneumococcal disease and strategies for its prevention: Proceedings of an international conference sponsored by Pasteur Merieux MSD held at the Royal Society of Medicine, London, 13 December 1994. Royal Society of Medicine Press, 1995.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Nuorti, J. Pekka. Prevention of pneumococcal disease among infants and children: Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine : recommendations of the Advisory Committee on Immunization Practices (ACIP). Dept. of Health and Human Services, Centers for Disease Control and Prevention, 2010.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

María, Mauricio Santa. Evaluación económica de la inclusión de la vacuna antineumocócica en el Plan Ampliado de Immunización. Fedesarrollo, 2008.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Siber, George R., Keith P. Klugman, and P. Helena Mäkelä, eds. Pneumococcal Vaccines. ASM Press, 2008. http://dx.doi.org/10.1128/9781555815820.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

New York Academy of Sciences. Pharmaceutical science to improve the human condition: Prix Galien 2011 : winners and finalist candidate of the Prix Galien USA Awards 2011. Wiley Periodicals, 2012.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Mäkelä, P. Helena, George R. Siber, and Keith P. Klugman. Pneumococcal Vaccines: The Impact of Conjugate Vaccines. Wiley & Sons, Limited, John, 2014.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Austrian, Robert, and Lewis Thomas. Life with the Pneumococcus: Notes from the Bedside, Laboratory, and Library. University of Pennsylvania Press, 2016.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Life with the pneumococcus: Notes from the bedside, laboratory, and library. University of Pennsylvania Press, 1985.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

van Assen, Sander, and Marc Bijl. Vaccination in immunocompromised adults. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0094.

Pełny tekst źródła
Streszczenie:
This chapter addresses all important questions regarding vaccination of patients with autoimmune inflammatory rheumatic diseases (AIIRD). First, the incidence of vaccine-preventable infections in these patients is discussed. Pulmonary infections, including influenza and pneumococcal infection, occur more often in AIIRD patients; herpes zoster and human papillomavirus are also more frequent. The efficacy of vaccination for all European registered vaccines is discussed. Treatment with disease-modifying anti-rheumatic drugs (DMARDs) and biologicals (in particular TNFα‎-blocking agents) do not ham
Style APA, Harvard, Vancouver, ISO itp.

Części książek na temat "Pneumococcal vaccine"

1

Eby, Ronald. "Pneumococcal Conjugate Vaccines." In Vaccine Design. Springer US, 1995. http://dx.doi.org/10.1007/978-1-4615-1823-5_31.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Dudley, Matthew Z., Daniel A. Salmon, Neal A. Halsey, et al. "Pneumococcal." In The Clinician’s Vaccine Safety Resource Guide. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-94694-8_14.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Dagan, Ron, and Keith P. Klugman. "Impact of Conjugate Pneumococcal Vaccine on Antibiotic Resistance." In Pneumococcal Vaccines. ASM Press, 2014. http://dx.doi.org/10.1128/9781555815820.ch25.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Madhi, Shabir A., and Keith P. Klugman. "Efficacy and Safety of Conjugate Pneumococcal Vaccine in the Prevention of Pneumonia." In Pneumococcal Vaccines. ASM Press, 2014. http://dx.doi.org/10.1128/9781555815820.ch22.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Whitney, Cynthia G., and Matthew R. Moore. "Direct and Indirect Effectiveness and Safety of Pneumococcal Conjugate Vaccine in Practice." In Pneumococcal Vaccines. ASM Press, 2014. http://dx.doi.org/10.1128/9781555815820.ch24.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Mäkelä, P. Helena, and Helena Käyhty. "Vaccine-Induced Immunity to Pneumococcal Infection." In The Pneumococcus. ASM Press, 2014. http://dx.doi.org/10.1128/9781555816537.ch25.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Bhalla, Manmeet, Shaunna R. Simmons, Essi Y. I. Tchalla, and Elsa N. Bou Ghanem. "Testing Anti-Pneumococcal Antibody Function Using Bacteria and Primary Neutrophils." In Vaccine Delivery Technology. Springer US, 2020. http://dx.doi.org/10.1007/978-1-0716-0795-4_33.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Reynolds, Kelly A., Deeti J. Pithadia, and Jashin J. Wu. "Pneumococcal Vaccine for 67-Year-Old Male on Adalimumab." In Clinical Cases in Psoriasis. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-18772-9_16.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Antao, Vinicius C., and William P. Hausdorff. "Global Epidemiology of Pneumococcal Disease—New Prospects for Vaccine Control." In Advances in Experimental Medicine and Biology. Springer US, 2008. http://dx.doi.org/10.1007/978-0-387-79838-7_2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Gray, Barry M., and Daniel M. Musher. "The History of Pneumococcal Disease." In Pneumococcal Vaccines. ASM Press, 2014. http://dx.doi.org/10.1128/9781555815820.ch1.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Pneumococcal vaccine"

1

Hinojosa, C. A., N. Borsa, A. Shaffer, et al. "Metformin Improves Pneumococcal Vaccine Responses in a Mouse Model." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7720.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Masuda, Toshihiro, Taisuke Akamatsu, Eiji Nakatani, et al. "Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa2627.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Mancuso, Peter, JoAnne Sonstein, Deepti Goel, Edmund O'Brien, and Jeffrey L. Curtis. "Leptin Is Required For Vaccine Induced Protection Against Pneumococcal Pneumonia." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a3278.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Bontsevich, Roman, Kristina Shchurovskaya, Galina Batisheva, et al. "Assessment of medical undergraduates’ relation to pneumococcal conjugate vaccine use." In ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa535.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Queiroz, Lis Vinhático Pontes, Janaína Seixas Pereira Meirelles, Maria Clara Sales do Nascimento, Thaísa Sobral de Andrade, and Kátia de Miranda Avena. "Meningitis in Brazil and its regions: a reflection on vaccination coverage in the last decade." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.618.

Pełny tekst źródła
Streszczenie:
Introduction: Meningitis is a potentially fatal disease. Vaccines play a fundamental role in its prevention, so it is important to reflect on the vaccination coverage (VC) performed in Brazil and in its regions. Objectives: To analyze the VC of meningitis in Brazil and regions in the last decade. Design and setting: Ecological study carried out in Brazil. Methods: Data were collected in the Information System of the National Immunization Program from the Computer Department of the Unified Health System between 2011 and 2020. The variables analyzed were: region, capitals and immunizers, which a
Style APA, Harvard, Vancouver, ISO itp.
6

Patil, Shital Vishnu, Sanidhaya Tak, Abdul Wahab Mirza, Arpit Johar, and Gurmaiher Singh Thethi. "Study of impact of pneumococcal vaccine in hospitalised community acquired pneumococcal pneumonia cases: A single center experience." In ERS Congress 2024 abstracts. European Respiratory Society, 2024. http://dx.doi.org/10.1183/13993003.congress-2024.pa5062.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

van Zandvoort, K., M. Bobe, A. Buqul, et al. "Modelling the potential impact of pneumococcal vaccination strategies in humanitarian crises." In MSF Scientific Day International 2023. MSF-USA, 2023. http://dx.doi.org/10.57740/cxek-yg24.

Pełny tekst źródła
Streszczenie:
INTRODUCTION Despite a likely high burden of disease caused by Streptococcus pneumoniae in humanitarian crises, pneumococcal conjugate vaccines (PCV’s) are rarely used in such settings. Routine immunisation is rarely feasible in crises, and there is little evidence on alternative delivery strategies for PCV. We used modelling to evaluate the effects of different vaccination strategies within humanitarian crisis settings, aiming to identify those which could quickly reduce and sustain low transmission of vaccine serotypes. METHODS We conducted a nested carriage and contact survey in a camp for
Style APA, Harvard, Vancouver, ISO itp.
8

Круглякова, Людмила, Lyudmila Kruglyakova, Светлана Нарышкина, et al. "EXPERIENCE IN VACCINE PROPHYLAXIS OF PNEUMOCOCCAL INFECTION IN THE PRECINCT POLYCLINIC." In XII International Scientific Conference (correspondence, electronic) "System analysis in medicine" (SAM 2018). Far Eastern Scientific Center of Physiology and Pathology of Respiration, 2018. http://dx.doi.org/10.12737/conferencearticle_5bdaacdd0e4199.34287133.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Williams, S. R., H. M. LeBuhn, A. J. Driscoll, K. M. Neuzil, W. H. Chen, and J. R. Ortiz. "Which Countries Have Adult Vaccine Programs? A Global Review of National Adult Influenza and Pneumococcal Vaccine Policies." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2146.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Tarasova, G., B. Belov, D. Bukhanova, et al. "SAT0397 Safety and immunogenicity of 23-valent pneumococcal vaccine in sle patients." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.3663.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Raporty organizacyjne na temat "Pneumococcal vaccine"

1

Ryan, Margaret A., Jamie A. McKeehan, and Gregory C. Gray. Pneumococcal Vaccine to Counter Emerging Infectious Disease Threat in the Military. Defense Technical Information Center, 2001. http://dx.doi.org/10.21236/ada408879.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Johnson, Edward G. Pneumococcal Vaccine Rates in Persons 65 and Older: A USAF Medical Facility Record Review. Defense Technical Information Center, 2001. http://dx.doi.org/10.21236/ada388268.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Alexandrova, Alexandra, Lena Setchanova, Daniela Pencheva, and Ivan Mitov. Molecular Serotyping of Serogroup 6 Streptococcus pneumoniae Isolates Has Shown Emergence of Serotype 6C After the Implementation of 10‑valent Pneumococcal Conjugate Vaccine (PhiD‑CV) in Bulgaria. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, 2019. http://dx.doi.org/10.7546/crabs.2019.08.14.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

CIOMS Guide to Active Vaccine Safety Surveillance. Council for International Organizations of Medical Sciences (CIOMS), 2017. http://dx.doi.org/10.56759/hnuw8440.

Pełny tekst źródła
Streszczenie:
With more vaccine solutions available and opportunities for earlier availability of new vaccine products in resource-limited countries (e.g. vaccines against rotavirus, human papillomavirus or pneumococci) as well as new products that address diseases endemic in those countries only (e.g. malaria, dengue among others), generating reliable data about specific safety concerns is becoming a priority for all countries. The Guide offers a practical step-by-step approach and algorithm to aid immunization professionals and decision-makers in determining the best course of action if additional vaccine
Style APA, Harvard, Vancouver, ISO itp.
5

Pneumococcal vaccines for people with COPD reduce their chance of catching pneumonia. National Institute for Health Research, 2017. http://dx.doi.org/10.3310/signal-000420.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Pneumococcal vaccine” dla poszczególnych typów źródeł:
Artykuły w czasopismach Rozprawy doktorskie
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii